Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Immunoconjugates (1):
Recent article
Immunoconjugates
Abstract
Our aim was to construct and characterize (111)In-nuclear translocation sequence (NLS)-7G3, an Auger electron-emitting radioimmunotherapeutic agent that preferentially recognizes the expression of CD123 (interleukin-3 receptor [IL-3R] α-subchain) in the absence of CD131 (IL-3R β-subchain) displayed...
|
PMID: 21816968
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Abstract
Despite large-scale efforts devoted to the conduct of clinical trials in systemic lupus erythematosus (SLE), no new therapy has been approved for treatment of this disease in more than 50 years. Increased understanding of the immunologic mechanisms underlying SLE has led to the devel...
|
PMID: 21584692
PDF is available here.
PDF is available here.
Abstract
Cardiovascular disease, the most common cause of death with a functioning graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs, particularly the calcineurin inhibitors. Belatacept, a selective co-stimulation blocker, may provide a better cardiovascu...
|
PMID: 21372756
PDF is available here.
PDF is available here.
Integrative Biology (3)4 2011
Abstract
We describe the design, production and characterization of a novel immunocytokine, in which murine interferon-alpha2 was sequentially fused with the tumor-targeting antibody fragment scFv(F8), specific to the alternatively-spliced EDA domain of fibronectin. The resulting fusion protein (F8-IFNa) cou...
|
PMID: 21225052
PDF is available here.
PDF is available here.
Abstract
We have described the generation of quorum quenching monoclonal antibodies (mAbs) against acyl homoserine lactones (AHL) used by Pseudomonas aeruginosa as well as Staphylococcal autoinducing peptides (AIP). These mAbs suppressed QS signaling in bacteria and neutralized AHL-mediated cytotoxic effects...
|
PMID: 21031321
PDF is available here.
PDF is available here.
Abstract
We discuss ways whereby we sought to treat myocardial infarctions using extracellular-matrix derived peptides. Using an ischemia/reperfusion myocardial infarction rodent model, we targeted these extracellular matrix-derived peptides to the myocardial infarct site and were able to induce angiogenesis...
|
PMID: 21048428
PDF is available here.
PDF is available here.
Abstract
Antibody-drug conjugates (ADCs), formed through the chemical linkage of a potent small molecule cytotoxin (drug) to a monoclonal antibody, have more complex and heterogeneous structures than the corresponding antibodies. This review describes the analytical methods that have been use...
|
PMID: 21441786
PDF is available here.
PDF is available here.
Abstract
B7 ligands deliver both costimulatory and coinhibitory signals to the CD28 family of receptors on T lymphocytes, the balance between which determines the ultimate immune response. Although B7-H4, a recently discovered member of the B7 family, is known to negatively regulate T cell im...
|
PMID: 21143433
PDF is available here.
PDF is available here.
Discovery medicine (10)53 2010
Abstract
Monoclonal antibodies (mAbs) and derivatives are currently the fastest growing class of therapeutic molecules. More than 30 G-type immunoglobulins (IgG) and related agents have been approved over the past 25 years mainly for cancers and inflammatory diseases. In oncology, mAbs are often combined wit...
|
PMID: 21034674
PDF is available here.
PDF is available here.
Abstract
These results suggest that the novel micelles could be a promising candidate with excellent therapeutic efficacy for targeting the drugs to cancer cells....
|
PMID: 20831277
PDF is available here.
PDF is available here.
Abstract
Currently used immunosuppressants exacerbate cardiovascular risk. However, attempts to limit the use of these agents increase the risk of allograft rejection. Immunosuppressants targeting signal 2 and signal 3 lymphocyte activation pathways are under clinical development. Clinical da...
|
PMID: 20706224
PDF is available here.
PDF is available here.
Immunotherapy (2)5 2010
Abstract
In the early 1990s, Linsley and colleagues produced a soluble fusion protein, comprising of the extracellular domain of cytotoxic T lymphocyte antigen (CTLA)4 and the human IgG1 Fc domain. Since then, several hundreds of scientific publications have demonstrated that CTLA4-Ig blocks...
|
PMID: 20874646
PDF is available here.
PDF is available here.
Abstract
We performed a Medline search for the period 2005 to March 2010, including the MeSH terms "SoJIA", "systemic juvenile idiopathic arthritis" and"biologicals", as well as an NIH study registry search. At Present there are scant and unconvincing data on the use of Etanercept or Adalimumab for the treat...
|
PMID: 20668866
PDF is available here.
PDF is available here.
Abstract
Since the middle of 1990s, the development of combinatorial chemistry along with the high throughput screening have led to some lack of interest for natural products from the pharmaceutical industry. Moreover, purification and optimization of natural compounds are very often difficult and animal exp...
|
PMID: 20637355
PDF is available here.
PDF is available here.
Abstract
Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts...
|
PMID: 20446121
PDF is available here.
PDF is available here.
Abstract
Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts...
|
PMID: 20446121
PDF is available here.
PDF is available here.
Abstract
Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts...
|
PMID: 20446121
PDF is available here.
PDF is available here.
Abstract
Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts...
|
PMID: 20446121
PDF is available here.
PDF is available here.
Abstract
Seven patients (6 females and 1 male) with a mean uveitis duration of 11.6 years entered the study. All patients had failed previous immunosuppressive therapy and >or=2 anti-TNFalpha treatments. All patients responded to abatacept and 6 maintained a clinical remission after a mean of 9.2 months of t...
|
PMID: 20191477
PDF is available here.
PDF is available here.
Abstract
The purpose of this study was to assess two-step in vivo tumor targeting by specific biotin-conjugated antibodies and ultrasmall superparamagnetic iron oxide (USPIO)-anti-biotin nanoparticles as contrast agents for magnetic resonance imaging (MRI) at 1.5 T.
D430B huma...
|
PMID: 19806404
PDF is available here.
PDF is available here.
Autoimmunity Reviews (9)8 2010
Abstract
During the last two decades fundamental changes have taken place in the treatment of patients with rheumatoid arthritis (RA). The effective establishment of methotrexate as the anchor drug and the introduction of new drugs, in particular anti-tumor necrosis factor (TNF) alpha blocker...
|
PMID: 20433955
PDF is available here.
PDF is available here.
Abstract
The mean labelling ratio of (211)At-labelled antibodies was 1:1,090 +/- 364 (range: 1:738-1:1,722) in comparison to 2-3:1 for GO. Tumour cell binding of (211)At-anti-CD33 was high in the presence of abundant CD33 expression and could be specifically blocked by unlabelled anti-CD33. (211)At-anti-CD33...
|
PMID: 20107790
PDF is available here.
PDF is available here.
Journal of Rheumatology (37)5 2010
Abstract
After 48 weeks of treatment, the proportion and the absolute number of circulating CD8+CD28- T cells decreased (p = 0.008, p = 0.055, respectively, compared with baseline), as well as the proportion of the CD8+CD45RA+CCR7- cells, thought to represent terminally differentiated effector T cells (p = 0...
|
PMID: 20231200
PDF is available here.
PDF is available here.
Clinical Nephrology (73)5 2010
Abstract
I and II clinical trials. This article reviews the mechanisms of action as well as published and preliminary results of the Phase I-III clinical trials involving these novel immunosuppressive agents....
|
PMID: 20420793
PDF is available here.
PDF is available here.
Abstract
Double-blind, randomized controlled trials have confirmed the role of alternative tumour necrosis factor (TNF) inhibitors (TNFi), rituximab, abatacept and tocilizumab, following TNFi failure with no comparative studies to date. Registry data have demonstrated efficacy of switching from a first to a...
|
PMID: 20190641
PDF is available here.
PDF is available here.
Neurological Research (32)3 2010
Abstract
We hypothesize that a short course of multiple costimulatory pathway blockade will be more effective in inhibiting the redundancy of the immune response and improve nerve regeneration through the nerve allograft.
The murine sciatic nerve allograft model was used to reconstruct a 1 cm sciatic nerve g...
|
PMID: 19570327
PDF is available here.
PDF is available here.
Abstract
These results validate immunotargeting by anti-ACE mAb conjugated with catalase as a prospective and specific strategy to augment anti-oxidative defence of the pulmonary endothelium during lung transplantation. Vascular immunotargeting of anti-oxidative enzymes could limit reactive oxygen species me...
|
PMID: 19948411
PDF is available here.
PDF is available here.
Drugs of Today (46)4 2010
Abstract
Belatacept is a fusion protein composed of the Fc fragment of a human IgG(1) immunoglobulin linked to the extracellular domain of cytotoxic T-lymphocyte-associated antigen 4 (CTLA4). CTLA4 is a molecule crucial for T-cell costimulation, selectively blocking the process of T-cell acti...
|
PMID: 20502720
PDF is available here.
PDF is available here.
Abstract
Abstract
We investigated whether antigen (Ag)-mediated T cell activation is required for PTH to exert its catabolic activity. We report that inhibition of Ag presentation through silencing of either class I or class II MHC-T cell receptor (TCR) interaction prevents the cortical bone loss induced by in vivo c...
|
PMID: 20392239
PDF is available here.
PDF is available here.
Abstract
English articles on abatacept, golimumab, and tocilizumab in rheumatoid arthritis published between 2002 and 2009 were reviewed systematically. All randomized clinical trials, open-label extensions, meta-analyses, and reviews were examined. There were thirteen articles on abatacept, four on golimuma...
|
PMID: 20195397
PDF is available here.
PDF is available here.
Abstract
The publication of the belatacept phase III studies offers a challenge in balancing benefits such as reduced burden of toxicity against risks such as EBV complications and more T cell mediated rejection.
|
PMID: 20415895
PDF is available here.
PDF is available here.
Abstract
The publication of the belatacept phase III studies offers a challenge in balancing benefits such as reduced burden of toxicity against risks such as EBV complications and more T cell mediated rejection.
|
PMID: 20415895
PDF is available here.
PDF is available here.
Abstract
Extracorporeal affinity adsorption treatment is a method that safely and efficiently reduces myelotoxicity associated with RIT. Extracorporeal affinity adsorption treatment allows increased administered activity without increased toxicity, with the aim of increasing the absorbed dose to the tumor. H...
|
PMID: 20127949
PDF is available here.
PDF is available here.
Abstract
Extracorporeal affinity adsorption treatment can be used to reduce the toxicity associated with administration of BR96-MMAF conjugates, making it possible to increase the amount of conjugates administered. The combined treatment will be further optimized in future studies.
(c) 2010 American Cancer S...
|
PMID: 20127954
PDF is available here.
PDF is available here.
Abstract
Immunoconjugates composed of the alpha-emitter (213)Bi and the monoclonal antibody d9MAb specifically target HSC45-M2 gastric cancer cells expressing mutant d9-E-cadherin. These conjugates efficiently killed tumor cells in a nude mouse peritoneal carcinomatosis model. To elucidate th...
|
PMID: 19139817
PDF is available here.
PDF is available here.
Abstract
I trials. AREAS COVERED IN THIS REVIEW: This review examines the preclinical and the published clinical data with regards to naptumomab. WHAT THE READER WILL GAIN: This review provides the reader with an understanding of the mechanism of action, immunology, pharmacokinetics and clinical activity of...
|
PMID: 20053143
PDF is available here.
PDF is available here.
Abstract
Antibodies are highly versatile proteins with the ability to be used to target diverse compounds, such as radionuclides for imaging and therapy, or drugs and toxins for therapy, but also can be used unconjugated to elicit therapeutically beneficial responses, usually with minimal toxicity. This upda...
|
PMID: 20187791
PDF is available here.
PDF is available here.
Abstract
Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder, characterized by spiking fever, skin rash, and arthritis. First-line treatment consists of corticosteroids. Methotrexate is commonly used in resistant cases or as a steroid-sparing drug. The availability of biologic drugs in the...
|
PMID: 20483052
PDF is available here.
PDF is available here.
Abstract
Optimal assessment methods depend on whether the outcome of interest is ability to detect treatment effects or to reflect patient satisfaction. Sustainability of response (and possibly, at a lower magnitude, fast onset of action) may be important when evaluating patient satisfaction with RA therapie...
|
PMID: 20483050
PDF is available here.
PDF is available here.
Abstract
T cells play a prominent role in the pathogenesis of rheumatoid arthritis. Abatacept is the first FDA approved agent for rheumatoid arthritis that blocks the activation of T cells by interrupting the interaction between the CD28 ligand on the T cell and the CD80/86 ligand on the anti...
|
PMID: 20969545
PDF is available here.
PDF is available here.
Discovery medicine (9)44 2010
Abstract
Abstract
We employed an anti-E-selectin monoclonal antibody to target tumors in vivo and evaluated an optical imaging reagent to visualize tumor regions. The anti-E-selectin antibody was conjugated on the surface of liposomes, which encapsulated the near-infrared fluorescent substances Cy3 or Cy5.5. The lipo...
|
PMID: 20235150
PDF is available here.
PDF is available here.
Abstract
Our study documented the most complete genetic information of Taiwanese AS patients. The observations that CTLA-4 +49A>G genotypes are associated with circulatory CRP levels and significantly less AS subjects carrying CTLA-4 higher-secretor −318 T allele suggest the level and regulation of inflamm...
|
PMID: 20030788
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
Monoclonal antibodies and their derivatives such as antibody fragments, immunoconjugates and Fc fusions, represent the majority of therapeutic proteins in clinical development. Recent successes of such molecules in cancer and in the treatment of autoimmune diseases found a great hope in biotherapeut...
|
PMID: 20035680
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
Our knowledge on antibody structure, in particular that of IgG1, largely used in the clinic, has progressed remarkably. However, some formidable challenges still remain to be confronted, among which the increase of a yet-limited antibody efficacy, the lowering of the frequency of serious clinical ad...
|
PMID: 20035672
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
The first treatment ever by radio-immunotherapy (RIT) was performed by William H. Beierwaltes in 1951 and was a success. Fifty years later, the main question is to find ways of extending the success of radiolabelled anti-CD20 antibodies in indolent non-Hodgkin's lymphoma to other forms of cancer. So...
|
PMID: 20035676
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
We know that the efficacy of an immunoconjugate depends not only on the coupled cytotoxic agent, but also on the selected target, the coupling method and the linker....
|
PMID: 20035677
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
Monoclonal antibodies (mAb) and related-products represent the fastest growing class of therapeutics in the biotechnological and pharmaceutical industry. In just as short as 20 years, more than 30 immunoglobulins (IgG) and derivatives have been approved in a wide range of indications (oncology, infl...
|
PMID: 20035674
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
We will discuss parameters which are taken into account to select monoclonal antibody or recombinant inhibitors. These include drug-related (target affinity, pharmacokinetics, mechanisms of action, etc.) and patient - (efficacy and side effects) or disease-related characteristics. Their impact on cu...
|
PMID: 20035675
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
Unwanted immunogenicity, i.e., the developpement by patients of anti-drug antibodies is a significant problem with biologicals therapeutic reagents and can compromise clinical response. Over 20 antibodies currently on the market and over 100 drug candidates are currently in clinical trials; all ther...
|
PMID: 20035681
PDF is available here.
PDF is available here.
médecine/sciences (25)12 2009
Abstract
Rituximab, a chimeric monoclonal anti-CD20 antibody, was introduced into clinical practice in 1997, and has proven to be highly effective in the treatment of B-lymphoproliferative disorders and autoimmune diseases. Despite such success, in vivo mechanisms of action of anti-CD20 have only recently be...
|
PMID: 20035683
PDF is available here.
PDF is available here.
Abstract
Clinical data for rituximab and abatacept demonstrate that both reduce disease activity in TNF-alpha antagonist inadequate responders, suggesting that agents with alternative mechanisms of action, such as those targeting key immune cells, may be useful in this patient population....
|
PMID: 19916731
PDF is available here.
PDF is available here.
Abstract
We investigated the potential of green fluorescent nanodiamonds as biomarkers in living cells. Nanodiamonds were functionalized by attaching antibodies that target intracellular structures such as actin filaments and mitochondria. Then, the nanodiamond conjugates were transfected into HeLa cells. Tr...
|
PMID: 19504515
PDF is available here.
PDF is available here.
Abstract
Allogeneic stem cell transplantation represents the most active form of anti-leukemic therapy in acute myeloid leukemia (AML). Advances in the transplant technology, availability of hematopoietic stem cells and supportive care not only have resulted in improved outcomes but also expanded the transpl...
|
PMID: 19860195
PDF is available here.
PDF is available here.
Abstract
Recently, three new biological agents, rituximab, abatacept and tocilizumab, have become available for the treatment of rheumatoid arthritis (RA) in patients with active disease, who have not responded to at least one disease-modifying antirheumatic drug (DMARD). Rituximab is an anti-CD20 monoclonal...
|
PMID: 19791825
PDF is available here.
PDF is available here.
Leukemia & Lymphoma (50 Suppl 1) 2009
Historical aspects and milestones in the development of effective treatment for hairy cell leukemia.
Abstract
Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, but is gratifying to treat for both physicians and patients. During the 50 years since its initial description as a clinical entity, hematologists have been fascinated by the bizarre appearance of the malignant cell with its ha...
|
PMID: 19814690
PDF is available here.
PDF is available here.
Abstract
Immunoconjugates of epirubicin were synthesized with monoclonal antibodies against the epidermal growth factor receptors, HER2/neu and EGFR, by creating a sulfhydryl-reactive epirubicin intermediate applying heterobifunctional succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC),...
|
PMID: 19480561
PDF is available here.
PDF is available here.
Transplantation (88)3 Suppl 2009
Abstract
Long-term results in renal transplantation are not as good as it has been expected. Thus, there is increasing interest in new immunosuppressive drugs and strategies. Among such strategies, antithymocyte globulin, particularly in calcineurin inhibitor-free protocols, may allow generation of regulator...
|
PMID: 19667957
PDF is available here.
PDF is available here.
Transplantation (88)3 2009
Abstract
We have sought to develop canine specific reagents.
We have created a fusion protein of the extracellular domain of canine (c) CTLA-4 linked to the hinge-CH2-CH3 domains of canine IgG1 in a pcDNA3.1+ vector. Chinese hamster ovarian cells were cotransfected with CTLA4-Ig vector and a...
|
PMID: 19667932
PDF is available here.
PDF is available here.